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Building solids inside nano-space: from confined
amorphous through confined solvate to confined
‘metastable’ polymorph†
K. P. Nartowski,a J. Tedder,a D. E. Braun,b L. Fa´bia´na and Y. Z. Khimyak*a
The nanocrystallisation of complex molecules inside mesoporous hosts and control over the resulting
structure is a significant challenge. To date the largest organic molecule crystallised inside the nano-pores
is a known pharmaceutical intermediate – ROY (259.3 g mol1). In this work we demonstrate smart
manipulation of the phase of a larger confined pharmaceutical – indomethacin (IMC, 357.8 g mol1), a sub-
stance with known conformational flexibility and complex polymorphic behaviour. We show the detailed
structural analysis and the control of solid state transformations of encapsulated molecules inside the pores
of mesoscopic cellular foam (MCF, pore size ca. 29 nm) and controlled pore glass (CPG, pore size
ca. 55 nm). Starting from confined amorphous IMC we drive crystallisation into a confined methanol solvate,
which upon vacuum drying leads to the stabilised rare form V of IMC inside the MCF host. In contrast to the
pure form, encapsulated form V does not transform into a more stable polymorph upon heating. The size
of the constraining pores and the drug concentration within the pores determine whether the amorphous
state of the drug is stabilised or it recrystallises into confined nanocrystals. The work presents, in a critical
manner, an application of complementary techniques (DSC, PXRD, solid-state NMR, N2 adsorption) to
confirm unambiguously the phase transitions under confinement and offers a comprehensive strategy
towards the formation and control of nano-crystalline encapsulated organic solids.
Introduction
The discovery of the M41S (MCM, Mobile Composition of Matter)
family of mesoporous silica materials extended the field of possible
applications of porous solids in catalysis, gas storage, size exclusion
chromatography and enzyme immobilisation in silica scaﬀolds.1–7
Furthermore, some unique features of mesoporous composites,
including an ordered, size tailored pore network, high pore volume
and high surface area drew the attention of the pharmaceutical
world to these materials as promising, multifunctional candidates
for drug delivery systems (DDS).8–10
Research on mesoporous silica materials for drug delivery
has focused mainly on two hosts, namely MCM-41 and SBA-15,
with pore sizes of ca. 4 and 8 nm, respectively. Van Speybroeck
et al. showed that SBA-15 may stabilise the amorphous state of
10 pharmaceutical molecules (including IMC) for over a period
of 6 months when entrapped inside the silica scaﬀold and
demonstrated their increased dissolution rates.11 Although the
volume of research published on the possible applications of
mesoporous silicas as crystallisation chambers is increasing,
molecular understanding of the phenomena which govern the
aggregation and self-assembly of molecules in porous media is
still to be fully achieved. One of the possible reasons for this
is the complexity of the system, in which the impact of the size
of confined clusters and the additional host–guest surface
interactions cannot be ignored. An attempt to understand glass
transition, vitrification and solidification of organic liquids
entrapped in nanometer scale pores was made by Jackson,
Alcoutlabi and McKenna.12–14 Unfortunately, all these findings
are concerned mainly with metals, small organic molecules,
liquids or polymers, which cannot be translated directly into
phase transitions of medium size complex molecules (including
pharmaceuticals), which may adopt more than one molecular
arrangement in the crystalline state (namely polymorphism).
Engineering of nano-crystals within controlled pore glasses
(CPG) and polymeric monoliths has been investigated during
the last decade. Polymorph selectivity in the crystallisation of
metastable forms of acetaminophen was reported by Beiner
et al. with further discussion of the impact of pore size on this
phenomenon by Rengarajan et al.15,16 Hamilton et al. showed
stabilisation of the metastable b-form of glycine inside porous
polystyrene-poly(dimethyl acrylamide) (p-PS-PDMA) monoliths
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and in CPG hosts with pore diameters less than 24 nm.
Furthermore, control of the orientation of the nanocrystalline
glycine or a,g-alkanedicarboxylic acids (HO2C(CH2)n2CO2H,
n = 3–13, odd) was achieved either by stereochemical inhibition
or chain length of the confined dicarboxylic acids.17–19 Despite
years of studies, to date the largest molecule with fully proven
crystallisation within mesoporous hosts is a pharmaceutical
intermediate, 5-methyl-2-[(2-nitrophenyl)-amino]-3-thiophene-
carbonitrile (ROY), which exhibits conformational flexibility
and a molecular mass of 259.3 g mol1.20
In this work we have studied nano-crystallisation of a much
larger (molecular mass 357.8 g mol1) model pharmaceutical
indomethacin (IMC) encapsulated within MCF (mesoscopic
cellular foam) and CPG porous solids via careful control of
the confined structures from amorphous to crystalline states.
With its well described polymorphism and phase transitions
IMC is a very good model compound for nano-crystallisation
research. SBA-15 mesoporous silica has been demonstrated to
be a suitable host for the stabilisation of amorphous IMC
loaded via incipient wetness method.11 An attempt to crystallise
IMC ‘inside’ the pores of MCM-41 and SBA-15 materials were
recently made by Ukmar et al.21,22 Although the authors suggested
selective crystallisation of one of the IMC polymorphs under
mesoscopic confinement, the presented data show typical bulk
fusion of IMC polymorphs and cannot be described as confined
crystallisation.22 Moreover, the spectroscopic data are consistent
with the presence of amorphous IMC in the pores, in agreement
with Van Speybroeck et al.11
In this work, for the first time we show multiple phase
transformations of the confined solids assuring in a critical and
comprehensive way that all transitions take place inside the
nanopores. Starting from confined amorphous IMC, through a
confined IMCmethanol (MeOH) solvate, we show a novel method
to crystallise and stabilise the rare and highly metastable IMC
form V*, a desolvation product.23,24 (*we expanded the nomen-
clature introduced by Borka,25 i.e. Roman numerals for anhydrate
polymorphs). We further demonstrate methods to control the
drug phase through the eﬀect of the pore size, loading procedure
and guest content, which is of paramount importance for further
industrial development.
Results and discussion
Indomethacin polymorphs – introducing solid-state NMR
studies on IMC methanol solvate and IMC form V
Indomethacin is a widely studied model pharmaceutical with well
recognised polymorphism and complex phase behaviour.25–43
Recent studies by Surwase et al. reported new crystalline forms
of IMC and water driven phase transitions from an amorphous
phase, in spite of years of studies.23
The thermodynamically most stable form of indomethacin
(g-IMC) has the space group symmetry P%1 with Z0 = 1. The g-IMC
crystal structure is stabilised by centrosymmetric R2
2(8) hydrogen
bonded ring motifs,44 formed between carboxylic acid groups.
g-IMC shows a melting point at 159.1 to 161.3 1C and an
enthalpy of fusion of 110 J g1.30,45,46 Metastable a-IMC is another
frequently occurring polymorph, which crystallises in the mono-
clinic space group P21 with Z0 = 3 and very diﬀerent conformations
compared to g-IMC. a-IMC exhibits a melting point in the range
from 153.0 to 155.0 1C with an enthalpy of fusion of 97.5 J g1.30,38
The methanol solvate crystallises in the monoclinic space
group P21/n (Z0 = 1), with a stoichiometric ratio of IMC :MeOH
of 1 : 1 (BANMUZ24). The solvate structure is stabilised by hydrogen
bonds between the carboxylic acid groups of indomethacin and
the alcohol groups of the methanol molecules, which form a
R4
4(12) ring motif. The solvent molecules are located in channels
along the crystallographic b axis, from which they may escape
easily during desolvation.47 The DSC curve (open pan) of
IMC methanol solvate shows an endothermic peak at an onset
temperature of 84 1C, which is in agreement with previous studies
and corresponds to the desolvation of the solvate to IMC form
V.35,47 A second endothermic event at 131.4 1C is related to the
melting of form V and followed by recrystallisation of the twomore
stable forms of IMC (a and g). Thus, IMC form V, often incorrectly
called d or form IV, can be obtained via slow desolvation of
the methanol solvate at room or elevated temperatures or under
vacuum.23,47 Based on our experience, a slow desolvation process
at room temperature may take up to 3 months, but leads to pure
form V, while much faster desolvation at elevated temperatures
often leads to a mixture of polymorphs (V, g, a).
The crystal structure of IMC form V is yet to be determined,
as this phase is a desolvation product showing low crystallinity.
The diﬀraction pattern of form V indexed to a monoclinic unit
cell (25 1C: a = 18.5450 Å, b = 5.4032 Å, c = 18.2967 Å, b = 95.6421)
using the first twenty peaks with DICVOL04 and the space group
was determined to be P21 based on a statistical assessment of
systematic absences, as implemented in the DASH structure
solution package.48,49
From the cell volume it was derived that there are two IMC
molecules in the asymmetric unit (Z0 = 2). IMC form V shows
small needles which melt between 130–131 1C followed by a
recrystallisation directly into g-IMC or a mixture of both a and
g-IMC.47 All DSC data of the reference samples are summarised
in Fig. 1B. The PXRD patterns of the reference samples (Fig. 1A)
are in good agreement with the simulated patterns for the IMC
structures published in the CSD (Cambridge Structural Database)
for structures INDMET (g-IMC, form I), INDMET02 (a-IMC, form II)
and BANMUZ (IMC methanol solvate).24,36,45,50 The PXRD pattern
of IMC:MeOH (1 : 1) solvate even after careful grinding shows two
strong intensity peaks with d(002) = 10.27 Å and d(004) = 5.15 Å,
which may be related to preferred orientation of the fine needles.
Furthermore, the PXRD pattern of form V IMC is in a good
agreement with those published previously.23,35 Indomethacin
has been studied widely using solid-state NMR spectroscopy,
complementing the single crystal structure determinations of
both the a- and g-polymorphs. The advanced solid-state NMR
methods focused on detailed analysis of hydrogen bonding
patterns and intramolecular distances and were supported by
first principles calculations.28,38,43,46,51
We report for the first time solid-state NMR spectra of IMC
methanol solvate and form V. Due to the fact that IMC form V is
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formed via desolvation of the IMC methanol solvate, we focus
on the changes in the peak positions and intensities for both
forms and compare them to the previously assigned peaks of the
spectrum of g-IMC (Fig. 2). Further, more detailed structural,
spectroscopic and computational studies of this indomethacin
polymorph V are in progress and will be presented elsewhere.
Similarly to g-IMC, the IMC methanol solvate has only one
indomethacinmolecule in the asymmetric unit (and an additional
Fig. 1 PXRD patterns (A) and DSC thermograms (B) of IMC polymorphs and MeOH solvate.
Fig. 2 (A) Hydrogen bonded R4
4(12) ring motif formed between IMC and methanol extracted from the IMC methanol solvate crystal structure
(BANMUZ); (B) Molecular diagram of IMC with labelled carbons; (C) 1H–13C CP/MAS NMR spectra of IMC polymorphs and methanol solvate (spinning
sidebands are labelled with asterisks).
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methanol molecule). This leads to a similar number of the
peaks in 1H–13C CP/MAS NMR spectra as in the spectrum of
g-IMC with one additional peak at 50.1 ppm arising from the
methanol carbon.
The majority of the aromatic peaks, the phenyl group and
carbons C-2, C-8, C-9 of the indole ring, undergo slight changes
when compared to g-IMC. The carboxylic acid carbon (C-11) peak
of the solvate undergoes three distinct changes, i.e. up-field shift
from 179.3 to 176.3 ppm, broadening and decrease in intensity.
The latter changes might be related to the close proximity of the
methanol molecules in the solvate, forming the R4
4(12) ring
motif, as shown in Fig. 2A.
The spectrum of IMC form V shows several diﬀerences as
compared to the IMC methanol solvate spectrum. Firstly, the
methanol carbon peak disappears and the C-12 peak undergoes
downfield shift from 54.1 to 56.2 ppm. Secondly, splitting and
decrease of the intensity of the peaks from carbons C-10 and
C-4 indicates the presence of two molecules in the asymmetric
unit, in agreement with the space group and unit cell parameters
derived from PXRD data. The carbon C-11 involved in the hydro-
gen bonding in the solvate undergoes a downfield shift, splitting
and decrease in intensity after desolvation, indicating the presence
of two magnetically non-equivalent carboxylic acid motifs.
Loading eﬃciency of silica hosts
Several methods have been applied for loading drug molecules
into the porous silica hosts, including impregnation, incipient
wetness, rotary evaporation, immersion, spray drying and melt
loading.8,52–56 The studies of crystallisation in the confined
space require accurate control of experimental protocols to
prevent the loading of the drug outside the pores. Furthermore,
it is important to note that distinguishing between the confined
drug species and the bulk phase outside the pore space often
presents a significant characterisation challenge.
We used two loading methods, i.e. incipient wetness and
melt loading method, for the encapsulation of indomethacin
and two diﬀerent types of the silica hosts. The first one was the
spherical MCF with ink-bottle like pores of 29.6 nm in diameter
interconnected by smaller windows (necks) of 11 nm as deter-
mined using nitrogen adsorption analysis. The second material
was commercially available unstructured CPG host with a mean
pore size diameter of 55 nm.
When the MCF silica host is loaded from the melt a gradual
decrease of the total pore volume and surface area as a function of
an increasing drug content are observed from nitrogen adsorption–
desorption isotherms, indicating loading of the drug inside the
pores. When the concentration of the embedded drug reaches
50 wt% (MCF–IMC 50–50) the pores seem to be fully filled with
the guest molecules.
A substantial increase in the total pore volume and the
surface area of the products loaded with high concentration of
the drug (MCF–IMC 70–30 and MCF–IMC 50–50) was observed
after addition of the solvent (Fig. 3 and 4, Table 1). This may
indicate dissolution and rearrangement of the confined amor-
phous phase prior to further crystallisation or some leakage of
the drug from the pores as melting of bulk crystalline IMC was
detected in DSC studies of the composites loaded with 30 and
50 wt% IMC (ESI:† S3, S6 and related figures). It is important to
mention that careful control over the solvent volume (lower than
Vtotal) and total content of the drug within the pores is crucial to
avoid leakage of the drug. Large volumes of solvent and high
drug content increase the risk of the drug leakage leading to
inhomogeneous composites (see ESI,† Fig. S2.4).
The CPG host with large pores of 55 nm in diameter can be
classified as being on the boundary between mesoporous and
macroporous silica materials (Table 2).
The combination of melting point depression (onset and
heat of fusion) and changes in N2 adsorption properties serve
as a proof of the guest confinement. The loaded CPG silicas
show some decrease of the BET specific surface area compared
to the pure host. However, the correlation between the drug
content and decrease of surface area is not straightforward
due to the relatively low value of the BET surface area of the
host (i.e. for the CPG material it is ca. 49.5 m2 g1 compared to
Fig. 3 Nitrogen adsorption–desorption isotherms of MCF host loaded with different ratios of IMC using the melting method (left) and MCF host loaded
with different ratios of IMC using the melting method and subsequently treated with MeOH (right). The isotherms are offset by 100 cm3 g1.
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333.2 m2 g1 for the MCF host (see the ESI,† S4, Table S4.1)).
The presence of crystalline guest embedded within the CPG host
can be illustrated by the broadening and decrease of the IMC
melting point, which is indicative of small crystals.14,57,58
Identification of the phase of the drug under mesoscopic
confinement
Melt loading method. The MCF and CPG hosts loaded using
the melting method at diﬀerent drug to host ratios do not show
signs of a crystalline phase, only a broad ‘halo’ signifying the
lack of long range order is visible in the PXRD patterns (ESI,†
S5, Fig. S5.1 and S5.2). These results are corroborated by the
solid-state NMR spectra of confined IMC within both the MCF
and CPG hosts (Fig. 5). The broadening of the indomethacin
peaks is due to the increased distribution of possible orienta-
tions and magnetically non-equivalent environments of carbon
atoms, typical of amorphous solids. The significant broadening
of the spectra from 160 to 180 ppm, corresponding to the
carboxylic acid carbon, may be related to the presence of a
variety of hydrogen bonding environments and orientations.
This could also be related to an increased mobility.59,60
Although thermal properties and phase transitions of confined
gases and liquids have been studied extensively, the eﬀect of
confinement on solids is still not understood fully. It is known
that nano-size crystals show a decrease and broadening of the
melting point and the melting enthalpy of confined crystals is
smaller in comparison to the bulk phase.14,57,58
Upon heating bulk amorphous indomethacin shows a
glass transition (Tg) at ca. 40 1C followed by recrystallization
of a- and g-IMC at 100–120 1C and the melting of the latter two
polymorphs.26 DSC thermograms of the MCF host loaded with
indomethacin using the melting method do not show any
crystallisation and melting processes, proving it is in an amor-
phous state (ESI,† S5, Fig. S5.3) and the size of the pores of MCF
(ca. 30 nm) prevents the thermally induced recrystallisation of
indomethacin. Interestingly, indomethacin confined within the
larger pores of the CPG host (ca. 55 nm) shows concentration
dependent thermally induced crystallisation (Fig. 6). No thermal
transitions were observed at low concentrations of IMC (up to
25% w/w). However, when the drug content reached 30 wt%
recrystallisation of the amorphous indomethacin into both
a- and g-IMC is observed. Such recrystallisation occurs inside
the pores, as confirmed by a decrease of the melting temperature
and broadening of the melting peak (for CPG–IMC 70–30 Tm
is 147.5 1C, for CPG–IMC 50–50 Tm is 146.8 1C). Nevertheless,
the two other peaks present on the DSC thermogram for the
materials loaded with IMC at concentrations of 30 and 50%
indicate the presence of the bulk crystalline a- and g-IMC, which
again signifies the importance of the loading protocol on the
crystallisation outcome.
Solvent induced amorphous to crystalline phase transition
in confined space. To drive indomethacin crystallisation from
an amorphous phase embedded within the porous MCF and
CPG hosts, three organic solvents, i.e. methanol, ethanol and
acetonitrile were used. It was reported previously that IMC
crystallisation from acetonitrile always leads to the formation
Fig. 4 Total pore volume and BET surface area of MCF–IMC melt loaded
samples before and after addition of the solvent. The total amount of IMC
within the materials was determined using TG analysis.
Table 1 Drug content in the MCF host and structural parameters of the host after loadinga
Host–guest composite IMC (g g1) Vtotal [cm
3 g1] dpore [nm] SBET [m
2 g1]
MCF N/A 1.613 29.6 333.2
MCF–IMC 85–15 0.151  0.003 1.290 26.2 233.9
MCF–IMC 80–20 0.199  0.010 1.225 30.0 220.1
MCF–IMC 75–25 0.243  0.016 1.134 23.3 203.0
MCF–IMC 70–30 0.294  0.010 0.880 25.8 167.8
MCF–IMC 50–50 0.494  0.013 0.056 N/A 28.1
MCF–IMC 85–15 + 0.28 mL MeOH 0.161  0.012 1.322 26.1 251.2
MCF–IMC 80–20 + 0.28 mL MeOH 0.191  0.070 1.206 23.1 260.0
MCF–IMC 75–25 + 0.28 mL MeOH 0.245  0.041 1.109 26.1 214.3
MCF–IMC 70–30 + 0.28 mL MeOH 0.261  0.027 1.042 26.0 204.8
MCF–IMC 50–50 + 0.28 mL MeOH 0.471  0.073 0.725 23.1 126.7
MCF 150 mg mL1 MeOH (0.8 mL g1)b 0.109  0.001 1.228 23.2 241.9
MCF 200 mg mL1 MeOH (0.8 mL g1)b 0.146  0.001 0.910 21.2 178.3
MCF 250 mg mL1 MeOH (0.8 mL g1)b 0.179  0.003 1.083 23.3 222.1
a Vtotal – total pore volume calculated at P/P0 of 0.99, dpore – pore size diameter calculated from the adsorption branch using the BJH (Barrett–
Jotyner–Halenda) method, SBET – the BET specific surface area.
b Loaded using IW method.
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of g-IMC, while crystallisation from ethanol may yield either the
a- or the g-polymorph depending on the supersaturation
ratio.25,29 Borka’s first paper on indomethacin polymorphs
indicated the formation of g-IMC in a bulk acetonitrile solution
and a-IMC on the walls of the crystallisation vial.25 Crowley and
Zografi reported the formation of IMC :methanol (1 : 1) solvate
from hot methanol at a low supersaturation ratio.35 As demon-
strated by Joshi et al. and later by Surwase et al. this solvate may
yield the metastable form V of IMC under careful desolvation.
This form was reported to recrystallise subsequently into more
stable polymorphs.23,47
The amorphous drug loaded within the MCF host at the
concentration of 30 and 50 wt% crystallises into a mixture of
IMC phases after addition of methanol, which are partly loaded
outside the pores. The DSC thermograms of both composites
with the highest loadings show the melting peaks of bulk g-IMC.
This can be related to a leakage of the dissolved drug from the
pores after addition of the solvent and recrystallisation on the
external surface of the host, since the presence of the bulk
crystalline phase in the highly concentrated samples could not
be detected before the addition of the solvent (ESI,† S6 and
related figures). The DSC thermograms of IMC confined within
the MCF pores show a decrease of the melting temperature and
broadening of the melting peak indicating the presence of nano-
size crystals (Fig. 7). The host loaded with 15% of IMC shows
no recrystallisation in the temperature range from 20 to 180 1C
confirming the presence of an amorphous phase, which is in
agreement with the PXRD data (Fig. 8). Increasing the host load
to 20% results in a mixture of amorphous and IMC form V. The
composites loaded with 20 and 25% of IMC, after treatment
with methanol, show a single melting point of form V IMC.
Table 2 Drug content within the CPG host after loading determined using TGA (n = 3)
CPG host loaded using
melting method IMC (g g1)
CPG host loaded using melting method
after addition of methanol IMC (g g1)
CPG–IMC 85 : 15 0.169  0.010 CPG–IMC 85 : 15 + 0.28 mL MeOH 0.150  0.001
CPG–IMC 80 : 20 0.218  0.008 CPG–IMC 80 : 20 + 0.28 mL MeOH 0.198  0.003
CPG–IMC 75 : 25 0.267  0.018 CPG–IMC 75 : 25 + 0.28 mL MeOH 0.231  0.002
CPG–IMC 70 : 30 0.285  0.024 CPG–IMC 70 : 30 + 0.28 mL MeOH 0.291  0.003
CPG–IMC 50 : 50 0.482  0.032 CPG–IMC 50 : 50 + 0.28 mL MeOH 0.484  0.001
CPG host loaded using IW method
with 0.6 mL g1 of material
IMC (g g1) CPG host loaded using IW method
with 0.75 mL g1 of material
IMC (g g1)
CPG 150 mg mL1 MeOH 0.069  0.018 CPG 150 mg mL1 MeOH 0.088  0.001
CPG 200 mg mL1 MeOH 0.112  0.004 CPG 200 mg mL1 MeOH 0.135  0.006
CPG 250 mg mL1 MeOH 0.133  0.007 CPG 250 mg mL1 MeOH 0.153  0.002
Fig. 5 1H–13C CP MAS NMR spectra of MCF and CPG hosts loaded with
molten IMC at different host : drug ratios.
Fig. 6 DSC thermograms of CPG host loaded with IMC from the melt at
diﬀerent host : drug ratios.
Fig. 7 DSC thermograms of MCF and CPG hosts loaded with IMC from
the melt after addition of methanol.
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This may indicate that spatial constrains of ca. 30 nm prevent the
concomitant crystallisation of form V and other phase impurities
(a- and g-IMC). Thus, phase pure form V can be obtained.
Using CPG host loaded with molten IMC at concentrations
15–25% we were able to obtain exclusively g-IMC after the addition
of ethanol or acetonitrile as a crystallisation driving solvent (ESI,†
S2). When methanol was used to drive IMC crystallisation either
pure IMC form V, with the methanol solvate as an intermediate,
or a mixture of both g-IMC and IMC form V were obtained. The
CPG–IMC composite loaded with 15% of indomethacin shows the
PXRD pattern and solid-state NMR spectrum of the pure IMC form
V (Fig. 8 and 9). At host–guest ratio of the CPG–IMC 80–20 and
the CPG–IMC 75–25, predominately indomethacin form V with
a small amount of g-IMC is formed (confirmed by the PXRD
and solid-state NMR). Further increase of the IMC content to 30
and 50% leads to the increase of the proportion of the drug
loaded outside the pores.
The DSC thermograms of the CPG host loaded with IMC
from the melt and subsequently treated with methanol show
several thermal events, which may be assigned to the melting of
IMC form V (below 125 1C), recrystallisation of a- and g-IMC,
corresponding to the only exothermic event following the form
V melting process, and finally the melting of a- (shoulder) and
g-IMC (o157 1C). Broadening and decrease of the melting
peaks of form V, as well as a- and g-IMC, indicates that all
observed phases are not bulk material, but are in the confined
space (Fig. 7, Table 3).
Neither solid-state NMR nor PXRD indicated the formation
of g- or a-IMC within the CPG–IMC 85–15 composite after
addition of methanol, suggesting that the presence of the
melting peaks at 146.5 1C (shoulder) and 152.1 1C are due to
recrystallisation of the a and g-IMC forms above the form V
melting point. Seeds of g and a-IMC may be present below the
PXRD and NMR detection limit and trigger the recrystallisation.
A decrease of the melting peak onset temperature of IMC form V
with increasing drug concentration in the CPG host is evident,
indicating a decrease of the size of the crystals. Full understanding
of the mechanism of thermal events in silica host loaded with
large amounts of IMC is beyond the scope of this work.
IMC–silica composites obtained via incipient wetness method.
Indomethacin loaded using the incipient wetness method into
both silica hosts shows different crystallisation products in
comparison to melt loaded composites. The presence of meta-
stable form V within loaded hosts was proven using PXRD, DSC
and solid-state NMR.
To investigate the impact of the added volume of the loading
solution on the final composition of the loaded hosts we used
0.6 and 0.75 mL g1 of a loading solution for the CPG and
0.8 mL g1 for the MCF material. These values were chosen
taking into account the total pore volume of the CPG and the
MCF hosts used in the study (1.18 and 1.61 cm3 g1 respectively).
PXRD patterns of the composites loaded with solutions of
diﬀerent indomethacin concentrations show peaks character-
istic for IMC form V (and g) (Fig. 10).
Due to overlapping and broadening of the peaks only traces
of g-IMC within the MCF composites can be detected, which is
corroborated by DSC results. CPG hosts loaded with a higher
volume of the loading solution (0.75 mL g1) show distinct
peaks of both crystalline phases (ESI,† S7, Fig. S7.1). This is
corroborated by DSC analysis, where thermograms show peaks of
bulk crystalline phases of IMC (ESI,† Fig. S7.2, and Table S7.1).
The DSC thermograms of CPG composites loaded using lower
volumes (150 and 200 mL mg1) of the loading solution show a
slightly broader melting endotherm of IMC form V and traces
(0.05–1.0% as determined from melting point onset tempera-
tures and heat of fusion) of bulk a- and g-polymorphs of IMC.
Furthermore, there is no exothermic recrystallisation event after
the melting of IMC form V. This indicates the formation of
confined IMC form V and the importance of the spatial con-
strains of silica walls in preventing the crystallisation of other
IMC polymorphs in the temperature range 20 to 170 1C. The
250 mg mL1 sample shows a distinct g-IMC melting peak.
Loading from the solution with the highest concentration of IMC
in methanol gives sharper form V melting peaks and a slightly
lower decrease of the melting onset which may indicate that IMC
form V is partly loaded outside the pores (Fig. 11, Table 4).
Fig. 8 PXRD patterns of MCF and CPG hosts loaded with molten indo-
methacin after treatment with methanol (peaks showing the presence of
g-IMC are labelled with asterisks).
Fig. 9 1H–13C CP/MAS solid-state NMR spectra of MCF and CPG hosts
loaded with molten IMC at different host : drug ratios subsequently treated
with methanol (peaks assigned to g-IMC are labelled with asterisks).
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The MCF host loaded with IMC from methanol using the IW
method shows the presence of confined form V IMC, bulk
g-IMC and small amounts of a-IMC. Although the loading
volume was much smaller than the total pore volume of the
MCF host, crystallisation outside the pores could not be avoided.
Similarly to the CPG hosts loaded with higher volumes of
loading solution (ESI,† Fig. S7.2, Table S7.1), the DSC thermo-
grams of MCF composites loaded with higher concentrations of
IMC loading solution (200 and 250 mg mL1 MeOH) show
melting of form V IMC preceded by a small endothermic event
at ca. 85 1C. This may be related to the presence of IMCmethanol
solvate (Fig. 11). The endotherm below 80 1C is related to the
evaporation of water from the silica surface, as water sorption
from the air may happen during sample preparation.
Solid-state NMR spectra of both hosts loaded using the IW
method at IMC concentration of 200 mg mL1 in methanol are
consistent with the presence of pure IMC form V within the
composites. No peaks of other IMC crystalline phases could be
detected, indicating that the presence of the g-IMC peak at high
loading concentrations of the MCF material is most likely due
to temperature induced recrystallisation of the bulk drug phase
loaded on the external surface of the host (Fig. 11 and 12).
The outcome of the deposition of the drug on the external
surface of the material is related to the concentration of the
loading solution. A high concentration of the guest molecules
in the loading solution (250 mg mL1) allows reaching reason-
able API content within the composite. This, however, leads to
the risk for some of the drug to be loaded outside the pores, as
Table 3 Thermal transitions corresponding to confined IMC form V in MCF and CPG hosts loaded from the melt after addition of the solvent
Host–guest composite Melting onset (1C) DHfusion (J g
1)
MCF–IMC 85–15 + 0.28 mL MeOH — —
MCF–IMC 80–20 + 0.28 mL MeOH 110.0 (form V) 18.3 (form V)a
MCF–IMC 75–25 + 0.28 mL MeOH 111.9 (form V) 35.8 (form V)
CPG–IMC 85–15 + 0.28 mL MeOH 122.6 (form V) 152.1 (g-IMC) 31.6 (form V) 18.6 (g-IMC)
CPG–IMC 80–20 + 0.28 mL MeOH 112.3 (form V) 150.1 (g-IMC) 25.6 (form V)b 26.5 (g-IMC)
CPG–IMC 75–25 + 0.28 mL MeOH 110.5 (form V) 149.6 (g-IMC) 24.1 (form V)b 25.9 (g-IMC)
a The lower measured heat of fusion value, compared to ‘MCF–IMC 75–25 + 0.28 mL MeOH’, indicates the presence of amorphous IMC. b Melting
of form V and recrystallisation of a- and g-IMC overlap, thus, the stated DHfusion values are too low.
Fig. 10 PXRD patterns of CPG host and MCF materials loaded with IMC
using IW method with 0.6 mL g1 of the solvent for CPG and 0.8 mL g1 of
the solvent for MCF.
Fig. 11 DSC thermograms of CPG and MCF hosts loaded with IMC using
IW method.
Table 4 Thermal parameters of CPG and MCF hosts loaded using IW
method from methanol
Host–guest composite Melting onset (1C) Melting peak (1C)
CPG 150 mg mL1 MeOH 126.9 (V) 130.6
CPG 200 mg mL1 MeOH 126.7 (V) 130.4
CPG 250 mg mL1 MeOH 129.9 (V) 132.1
MCF 150 mg mL1 MeOH 128.3 (V) 131.4
159.7 (g) 160.1
MCF 200 mg mL1 MeOH 127.6 (V) 132.1
159.5 (g) 160.1
MCF 250 mg mL1 MeOH 127.5 (V) 131.7
159.5 (g) 160.1
Fig. 12 1H–13C CP/MAS solid-state NMR spectra of CPG and MCF hosts
loaded using IW method at indomethacin concentration in methanol of
200 mg mL1.
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crystallisation of the supersaturated solution may start in
contact with the external surface of silica.
Results summary. In this paper we demonstrate the impact
of mesoscopic confinement, loading method, drug content
within the pores and subsequent solvent treatment of melt
loaded composites on the formation of the nano-size crystals of
the model pharmaceutical compound indomethacin (Scheme 1).
It is possible to prevent the thermally induced recrystallisation of
the amorphous indomethacin confined within the pores of the
MCF host using a whole range of host guest ratios (up to 50% of
drug content).
Thermally induced recrystallisation of indomethacin con-
fined within the CPG host was prevented at up to the 30% drug
content within the pores. This indicates an increased possibility
for molecules to form diﬀerent supramolecular assemblies
within the pores, which can lead to polycrystalline composites.22
Addition of methanol to the melt loaded MCF composites
drives the crystallisation of the methanol solvate and upon
vacuum drying IMC form V is obtained (at drug concentrations
within the silica pores from 20 to 25 wt%). Interestingly, con-
fined form V does not show any recrystallisation upon heating,
indicating that spatial constrains and the crystallisation method
allowed us to readily produce phase pure methanol solvate and
phase pure form V. Phase purity of the intermediate solvate and
form V is crucial if one aims at preventing/slowing down the
transformation to any of the other more stable IMC polymorphs.
The addition of the solvent to the MCF composite loaded with
IMC at a concentration of 15% does not drive crystallisation into
any of crystalline forms of IMC. This may indicate both strong
interactions between the drug and the silica walls and/or the
insuﬃcient number of drug molecules to form nuclei large
enough to form a crystal.
Methanol driven crystallisation of amorphous indomethacin
inside the larger pores of the CPG host shows the formation of a
mixture of forms within the whole range of investigated host–
guest ratios. However, a proportional preference towards the
most stable g-IMC with an increase in drug content is observed.
The addition of either ethanol or acetonitrile to the melt loaded
CPG composites leads to an exclusive recrystallisation into the
most stable g-IMC (see the ESI,† S2). This highlights the impor-
tance of both the nature of the confinement medium and
the solvent on the formation of nanoscale confined crystals.
Scheme 1 Summary of possible amorphous to crystalline transformations of melt loaded indomethacin under confinement of MCF and CPG hosts.
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The amount of guest molecules that can be successfully embedded
within the silica hosts depends on a careful design of the loading
procedure. The maximum loading capacity of the host might be
overestimated due to the obstruction of the pores, especially
when high drug loading is needed. A uniform distribution of the
drug within the host material during mixing helps to avoid the
presence of drug rich domains which cannot be loaded fully into
the pores by a capillary action and may lead to some drug being
left on the external surface. Finally, the heating temperature
needs to be sufficiently high to melt the guest, while avoiding its
decomposition.
The incipient wetness method is one of the solvent mediated
methods for drug loading into the mesoporous silica hosts.
However, it is much more diﬃcult to control as increasing drug
concentration within the loading solution increases risk of
the spontaneous crystallisation of the supersaturated solution
outside the pores. In case of indomethacin it can even lead to
the formation of an elusive polymorph, IMC form V.
Conclusions
Mesoporous silica materials with pore diameters of up to 8 nm
(MCM-41 and SBA-15) have been widely studied as drug delivery
systems to stabilise amorphous phases. We have demonstrated
that an increase in the pore size diameter of mesoporous silicas
may lead to exciting changes in the crystallisation behaviour of
a widely studied pharmaceutical compound indomethacin.
Amorphous IMC can be stabilised when embedded within
pores of ca. 30 nm using the melting method, whereas the
CPG host with pores of ca. 55 nm can stabilise the amorphous
phase only at low drug content within the composite. Further-
more, addition of a solvent to the melt loaded systems leads
to the formation of nano-scale crystals inside the pores. The
polymorphic phase formed under confinement depends on the
pore size, embedded drug content and crystallisation solvent.
Guest loading using the IWmethod leads directly to the formation
of a crystalline phase. Thus, by choosing the right conditions it is
possible to increase the solubility, which might be crucial for a
poorly water soluble compound as indomethacin.
In this study, we have used a novel approach to investigate
phase transitions inside silica based, nano-scale crystallisation
chambers with well organised systems of pores, i.e. MCF hosts.
Combined application of nitrogen adsorption–desorption analysis,
thermal and diffraction methods and solid-state NMR enabled us
to gain a much better control over the phase and transformations
of the guest in the final products, which may lead to a better
understanding of host guest interactions within drug delivery
systems based on mesoporous silica composites. Furthermore,
we have demonstrated a new method for the formation and
stabilisation of IMC form V using mesopores to prevent recrys-
tallisation into more stable IMC polymorphs. This should
enable further studies of MCF based nano-crystalline drug
delivery systems and highlights the importance of loading
methods and laboratory procedures on the final product, which
is of the interest for the pharmaceutical industry. 13C solid-state
NMR spectra of IMC methanol solvate and IMC form V were
presented for the first time, highlighting the main structural
changes related to the desolvation.
Mesoporous silicas with large pores are not only promising
systems for nano-crystalline drug delivery systems, but are also
well defined model materials for the investigation of early
stages of crystallisation.
Possible tailoring of the pore size diameter may enable
eﬀective control of the maximum size of critical nucleus during
crystal formation. Furthermore, functionalisation of the inter-
nal surface of the silica host may target a particular hydrogen
bonding motif on crystallisation outcome.
Experimental
Indomethacin, Pluronic P123, 1,2,3-trimethylbenzene, tetraethyl
orthosilicate (TEOS), ammonium fluoride, 37 wt% hydrochloric
acid, methanol, ethanol and acetonitrile were purchased from
Sigma Aldrich and used without further purification.
Mesoporous host synthesis
Spherical particles of Mesostructured Cellular Foam (MCF)
were synthesised using the method described by Han et al.61
Briefly, 4 g of tribloc co-polymer Pluronic P123 were dissolved
in 75 mL of 1.5 M HCl. After that 4 g of swelling agent (1,3,5-
trimethylbenzene) was added and the resulting solution was
heated to 40 1C in a water bath and stirred vigorously for
2 hours. Subsequently, 9.2 mL of TEOS as a source of silica
was added dropwise to the polymer solution and stirred for
another 5 min. The mixture was then transferred to a PTFE
bottle and aged at 40 1C for 20 hours without stirring. After that
time 46 mg of NH4F was added to the mixture and aged at
100 1C for another 24 hours. The resulting white solid was
filtered, washed with MiliQ-quality water and ethanol and dried
in an oven at 40 1C for 24 hours. The dried powder was then
calcined in air at 650 1C for 10 hours.
Controlled Pore Glass (CPG), developed by Haller, is a rigid
glass containing a network of interconnected pores.62 The glass
is formed by a phase rearrangement process of alkali borosili-
cate glasses at elevated temperatures.63,64 Control of the time
and the temperature of the process enables tailoring of the pore
size diameter and leads to a narrow distribution of the pores.
The product obtained after leaching forms a continuous,
silica rich glass with a porous network of specified pore
dimensions. The CPG material is used mainly in the exclusion
and absorptive chromatography of biomolecules and, due to
the possible organofunctionalisation of its internal surfaces, as
a support for the immobilisation of bio-reactive molecules.31
In our study commercially available (Merck Millipore) CPG
material with a pore size of 550 Å served as a nano-size
crystallisation chamber for the investigation of IMC phase
changes under confinement. Scanning electron microscopy
images of the synthesised MCF spherical particles and the
CPG particles are shown in ESI† (Fig. S1.1).
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Indomethacin recrystallisation
The indomethacin purchased from Sigma Aldrich was g-IMC
(form I45). a-IMC (form II36) was formed by dissolving 300 mg of
the drug in 40 mL of warm ethanol in a round bottom flask and
evaporation of the solvent using a rotary evaporator at 50 1C.
The resulting powder was then ground in a mortar and analysed
using DSC (Diﬀerential Scanning Calorimetry), PXRD (Powder
X-ray Diﬀraction) and solid state NMR. An IMC :MeOH (1 : 1)
solvate was obtained using the method described by Joshi et al.47
Briefly, 500 mg of IMC was dissolved in 8 mL of methanol at
80 1C and left on a bench at room temperature in a vial covered
by parafilm to reduce evaporation. Fine needles were collected
after two days and dried using a filtering paper. The stoichio-
metric ratio between the solvent and IMC was confirmed using
thermogravimetric analysis. A reference sample of IMC form V
was obtained by the slow desolvation of the IMC :MeOH (1 : 1)
solvate at room temperature for two months under a perforated
parafilm cover.
Drug loading methods
Loading from the melt. The CPG or the MCF material
(200 mg) was mixed with IMC in a glass vial (15 mL) for three
minutes using a spatula to obtain host : drug weight ratios of
85 : 15, 80 : 20, 75 : 25, 70 : 30, 50 : 50 and put into a vacuum oven
(200 mbar) at 165 1C for 2 hours (i.e. a temperature above the
melting point of g-IMC). The loaded composites were then
cooled to an ambient temperature and stored in a desiccator
at 4 1C. The presence of an amorphous phase was confirmed
using DSC, PXRD and solid-state NMR. Composites loaded from
the melt were labelled as follows: host–IMC (host is CPG or MCF)
and host–guest ratio (e.g. CPG–IMC 85–15).
Phase transformation of amorphous IMC under confine-
ment. Typically, to drive IMC crystallisation from an amorphous
phase, 280 mL of methanol were added dropwise to 200 mg of
IMC–host composite loaded from the melt. The wetted samples
were then mixed promptly and thoroughly with a spatula for
30 seconds to allow a uniform filling of the pores with the
solvent and left on a bench at room temperature in the sealed
glass vials for 24 hours. Subsequently, the materials were dried
under vacuum at 40 1C for 2 hours and stored in a desiccator at
4 1C. The volume and solvent addition procedure were carefully
optimised (ESI,† S2 and related figures). Composites loaded
from the melt and subsequently treated with methanol were
labelled as follows: host–IMC (CPG or MCF), host guest ratio
+0.28 mL MeOH (e.g. CPG–IMC 85–15 + 0.28 mL MeOH).
Incipient wetness loading method. Indomethacin loading
solutions were prepared by dissolving the drug in a vial in hot
methanol to obtain concentrations of 150, 200 and 250 mg mL1.
To investigate the eﬀect of the volume and the concentration of
the loading solution on the IMC phase formation, 120 mL or
150 mL of the IMC solution was then added dropwise to 200 mg
of the CPG host and 160 mL of the same loading solution was
added to the MCFmaterial. The loaded host was mixed promptly
and thoroughly with a spatula to obtain uniform loading
and evaporate any excess of the solvent from the sample.
Subsequently, the composites were dried under vacuum
(200 mbar) at 40 1C for 12 hours. The dried samples were then
stored in a desiccator at 4 1C. The volume of the loading
solution was adjusted to the total pore volume of the silica
hosts, resulting in theoretical loadings of the pores in 50 and
75% in the case of the CPG host and 50% of the MCF host.
Incipient wetness loaded materials were labelled using the host
name and the concentration of IMC in the loading methanol
solution (e.g. CPG 200 mg mL1 MeOH).
Characterization methods
Gas sorption analysis. Nitrogen adsorption–desorption iso-
therms were measured using a Nova 2200e Surface Area and
Pore Size Analyzer (Quantachrome, Hook, UK) at 196 1C. All
samples were outgassed under a high vacuum at 40 1C for
12 hours before the analysis to avoid any temperature driven
recrystallisation of the loaded drug. The BET specific surface
area was calculated over a relative pressure range from 0.05 to
0.20 assuming monolayer coverage and using 0.162 nm2 as the
molecular area of nitrogen. The pore size distribution curves
were calculated using the Barrett–Joyner–Halenda (BJH) algorithm
using the Broekhoff–de Boer method for the estimation of
adsorbed statistical film thickness. The size of the pore windows
of the MCF host was calculated from the desorption branch of the
isotherms, whereas the size of the main pores was calculated from
the adsorption branch of the isotherms.61,65
Loading eﬃciency. The drug content was determined using
a TQ 500 thermogravimetric analyser (TA Instruments, New
Castle, DE, U.S.). All samples (5–10 mg) were heated from 25 to
100 1C using a heating rate of 10 1C min1 and left isothermal
for 10 min at 100 1C to remove residual water adsorbed on the
material surface. Subsequently, the samples were heated from
100 to 600 1C using a heating rate of 20 1C min1 and left at
600 1C for 15 min to decompose all loaded drug. Finally, the
analysed samples were heated to 630 1C and cooled to 25 1C.
All measurements were made using platinum pans. A sample
nitrogen purge flow of 25 mLmin1 and a balance purge flow of
10 mL min1 were applied. The results were analysed using the
TA Instruments Universal Analysis 2000 software (TA Instruments-
Waters LLC).
Diﬀerential scanning calorimetry analysis. All DSC studies
were performed using a Q 2000 MTDSC instrument (TA Instru-
ments, New Castle, DE, U.S.). Calibration was performed using
indium, tin and n-octadecane. Standard crimped TA 100 mL
aluminium pans were used in all experiments. Only IMC
methanol solvate was analysed in an open pan.47 The weights
of pure crystalline IMC samples were 2–4 mg, whereas weights
of the loaded hosts were 8–10 mg to increase crystalline phase
detectability. A nitrogen purge of 50 mL min1 was used. All
experiments were carried out within the range of temperatures
from 20 to 170 1C using a heating rate of 5 1C min1. Results
were analysed with the TA Instruments Universal Analysis 2000
software (TA Instruments-Waters LLC).
Powder X-ray diﬀraction. Powder X-ray diﬀraction patterns
were acquired using an ARLTM X’TRA Powder Diﬀractometer
(Thermo Fisher Scientific Inc., Waltham, MA, U.S.) employing
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Cu Ka radiation (l = 0.1540562 nm) in the range of 2y from 5 to
361. A step size of 0.011 and a scanning rate of 2 s per step for
the crystalline reference samples of the IMC polymorphs and
6 s per step for the loaded materials were applied.
Scanning electron microscopy. Size and morphology of
porous hosts were studied using a JSM 4900 LV (JEOL Ltd,
Japan) electron microscope at 20 kV. Samples were gold coated
prior to the analysis.
Solid-state NMR. 1H–13C cross-polarization/magic angle
spinning (CP/MAS) solid-state NMR spectra were acquired at
400.23 MHz for 1H and 100.64 MHz for 13C using a Bruker
AVANCE III solid-state NMR spectrometer using RAMP CP pulse
sequence. The MAS rate was 10.0 kHz, the 1H p/2 pulse length
and pulse delay were optimised to 3.20 ms and 10.0 s. The contact
time during CP was set to 2.0 ms and SPINAL64 decoupling was
applied during the acquisition. The Hartmann–Hahn conditions
were set with hexamethylbenzene (HMB). Typically 1024 scans
were acquired for pure crystalline phase and 6144 scans for
loaded materials. The 13C chemical shifts were recorded with
respect to TMS.
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